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Increasing evidence suggests tumors aremaintained
by cancer stem cells; however, their nature remains
controversial. In a HoxA9-Meis1 (H9M) model of
acute myeloid leukemia (AML), we found that
tumor-initiating activity existed in three, immunophe-
notypically distinct compartments, corresponding
to disparate lineages on the normal hematopoietic
hierarchy—stem/progenitor cells (Linkit+) and com-
mitted progenitors of the myeloid (Gr1+kit+) and
lymphoid lineages (Lym+kit+). These distinct tumor-
initiating cells (TICs) clonally recapitulated the immu-
nophenotypic spectrum of the original tumor in vivo
(including cells with a less-differentiated immuno-
phenotype) and shared signaling networks, such
that in vivo pharmacologic targeting of conserved
TIC survival pathways (DNA methyltransferase
and MEK phosphorylation) significantly increased
survival. Collectively, H9M AML is organized as an
atypical hierarchy that defies the strict lineage
marker boundaries and unidirectional differentiation
of normal hematopoiesis. Moreover, this suggests
that in certain malignancies tumor-initiation activity
(or ‘‘cancer stemness’’) can represent a cellular state
that exists independently of distinct immunopheno-
typic definition.
INTRODUCTION
The cellular and molecular heterogeneity characterizing tumors
posesachallenge for therapyandhasbeenclassically interpreted
through two opposing models. The stochastic model states
all tumor cells have an equal probability of regenerating the
disease and must be targeted for curative therapy (Shackleton
et al., 2009). The cancer stem cell (CSC)model posits that tumors
are hierarchically organized and maintained by CSCs (also
called tumor-initiating cells [TICs]), which uniquely self-renew,
produce the heterogeneous lineages composing the bulk tumor,
and must be eradicated for curative therapy (Clevers, 2011).210 Cell Stem Cell 10, 210–217, February 3, 2012 ª2012 Elsevier IncOriginal support for the CSC model came from human AML in
which only the rare subset of cells resembling hematopoietic
stem/progenitor cells (HSPCs) could initiate disease upon xeno-
transplantation (Bonnet and Dick, 1997). Putative CSCs were
also identified in solid tumors, and CSCs were thought to be
rare and have an undifferentiated phenotype, like tissue-specific
stem cells (Ricci-Vitiani et al., 2007). Other work challenged this
paradigm, showing TICs need not be rare (Kelly et al., 2007;
Quintana et al., 2008) and that tumor cells with immunopheno-
types of mature progenitors or lineage cells could perform as
functional TICs in human and mouse AML (Deshpande et al.,
2006; Eppert et al., 2011; Goardon et al., 2011; Sarry et al.,
2011; Somervaille and Cleary, 2006; Taussig et al., 2010). These
conflicting data underscore the challenge of defining CSCs and
call into question whether the developmental structure of normal
stem cell systems is maintained, or mimicked, in cancer (Dick,
2008; Jordan, 2009).
Independent of these hypotheses, incontrovertible links exist
between cancer and the dysregulation of stem cell develop-
mental pathways. Homeobox (Hox) genes are important for
hematopoietic development and stem cell self-renewal (Abra-
movich and Humphries, 2005), and ectopic expression of
Hoxa9 and Meis1 (H9M) in hematopoietic progenitors leads to
rapid onset AML (Kroon et al., 1998). This H9M AML model
has yielded insights into the molecular (Bmi-1) and extracellular
factors (Wnt/b-catenin signaling) underlying CSC maintenance
(Lessard and Sauvageau, 2003; Wang et al., 2010). We demon-
strate that enforced H9M expression leads to a reproducible
breakdown of the normal flow of differentiation, driving the
formation of multiple, phenotypically distinct TICs, and resulting
in a malignancy organized as an atypical, dynamic hierarchy in
which tumor-initiating activity (TIA) exists as a cellular ‘‘state’’
that is largely independent of immunophenotype.
RESULTS
Multiple TICs in H9M AML
Normal HSPCs express c-kit, lack mature lineage markers, and
produce c-kit expressing myeloid or lymphoid progenitors that
give rise to mature cells (Figure S1A available online). Four
unique/expanded populations in H9M mice were assessed for
TIA: (1) Linkit+, lacking mature markers and expressing c-kit,
analogous to an HSPC; (2) Lym+kit+, coexpressing lymphoid.
Figure 1. Multiple, Immunophenotypically Distinct Compartments Possess Tumor-Initiating Activity
(A and B) Immunophenotypic comparison of bone marrow from mice transplanted with (A) GFP or (B) H9M-GFP transduced progenitors. In (i), flow cytometric
analysis is shown. ‘‘Lym’’ is a cocktail of B- and T cell markers (B220, CD19, CD3ε, CD4, CD8a, and TCR-b). PI is propidium iodide. In (ii), SPADE analysis of
immunophenotypic progression is shown. The size of each circle (metacell) indicates relative cell frequency. Metacell clusters were manually annotated based on
(iii) c-kit, (iv) lymphoid cocktail, and (v) Gr1 expression. These parameters and CD11b used for tree drawing.
(C) FACS-purified populations from H9M-GFP marrow were sorted and plated in methylcellulose with SCF, GM-CSF, IL-3, and IL-6 (S36GM). Colonies were
scored after 7 days, dissociated, and replated. Numbers per 1000 cells plated (in triplicate ± SEM). Total WT-GFP cells are shown as a control.
(D) Survival curves of mice lethally irradiated and transplanted with indicated numbers of cells (plus 105 helper marrow) from following compartments: Linkit+
(blue, 102 cells), Lym+kit+ (red, 102 cells), Gr1+kit+ (green, 102 or 103 cells), or Gr1+kitlo (purple, 102 or 103 cells). See also Figures S1 and S2.
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Multiple Tumor-Initiating Cells in H9M AMLmarkers and c-kit, analogous to a lymphocyte precursor;
(3) Gr1+kit+, coexpressing c-kit and myeloid markers, represent-
ing an immature myeloid cell; and (4) Gr1+kitlo, resembling
a mature myeloid population (compare WT and H9M immuno-
phenotypes, Figures 1Ai and 1Bi and Figures S1E–S1J). The
difference between the hematopoietic continuum of WT and
H9Mmarrow was also visualized with SPADE, a density normal-
ization, agglomerative clustering, and minimum-spanning tree
algorithm that distills multidimensional single-cell data to inter-
connected ‘‘relatedness’’ clusters (with corresponding popula-
tions in conventional flow plots) of metacell populations dis-
played as a 2D tree plot (Figures 1Aii–Av and 1Bii–1Bv; Qiu
et al., 2011). The SPADE tree, drawn with composite data from
WT-GFP, primary and secondary H9M-GFP cells, facilitatedCecomparison of common and distinct metacells in each condi-
tion (size indicates relative frequency; compare Figure 1Aii
with Figure 1Bii). As expected, in WT-GFP, the rare, c-kit-
expressing progenitors lacked lineage marker expression
whereas lymphoid metacells largely cluster together and are
distinct from the myeloid region (Figures 1Aiii–1Av). In contrast,
H9M-GFP cells have increased c-kit expression in the progen-
itor and myeloid regions and a diminished lymphoid population
(Figures 1Biii–1Bv).
The Linkit+, Lym+kit+, Gr1+kit+, and Gr1+kitlo compartments
were assessed for TIA. In retroviral transplant models, in vitro
myeloid colony-forming cells are TICs (Somervaille and Cleary,
2006). Each population was sorted to high purity and colony-
forming activity (CFA) was assessed. The Linkit+ and,ll Stem Cell 10, 210–217, February 3, 2012 ª2012 Elsevier Inc. 211
Figure 2. Enforced H9M Expression Permits Surface Marker Plasticity in TIC Resulting in a Dynamic Tumorigenic Hierarchy
(A) Flow cytometry of representativemarrow from secondary mice transplanted with indicated cell number from specified compartment. Shaded region indicates
the population transplanted.
(B) As shown in (Bi), single cells from primary AML were expanded into colonies and after 1 week transplanted into secondary mice. Shown in (Bii) is flow
cytometric analysis of the GFP+ marrow compartment of secondary mice transplanted with single-cell derived Lym+kit+ colony (top) or Gr1+kit+ colony (bottom).
(C–F) Survival curves from mice transplanted with 100 primary or secondary (C) Linkit+, (D) Lym+kit+, (E) Gr1+kit+, or (F) Gr1+kitlo cells. See also Figure S3.
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Multiple Tumor-Initiating Cells in H9M AMLunexpectedly, Lym+kit+ compartments had robust myeloid CFA
(>10%; Figure 1C). In contrast, the Gr1+kit+ cells had low initial
CFA (<1%), which increased upon replating; Gr1+kitlo cells
lacked any CFA. The most stringent test of TIA is transplanting
disease with limiting cell numbers in vivo (Clarke et al., 2006).
All recipients transplanted with 100 primary Linkit+ or Lym+kit+
cells succumbed rapidly to disease while more than 1000 Gr1+
kit+ and 10,000 Gr1+kitlo cells were required to initiate disease
in secondary recipients (Figure 1D and Figures S2A and S2B).
Therefore, primary H9MAML is organized as a hierarchy in which
multiple, phenotypically distinct TICs (Linkit+, Lym+kit+) are
enriched for TIA and give rise to differentiated blasts (Gr1+kitlo)
lacking TIA. The Gr1+kit+ compartment in primary AML has
low, but seemingly selectable TIA.212 Cell Stem Cell 10, 210–217, February 3, 2012 ª2012 Elsevier IncStage-Dependent Differentiation Is Separate from TIA
Constitutive GFP expression allowed in vivo lineage tracking of
TIC progeny. Each c-kit+ compartment recapitulated the entire
immunophenotypic spectrum of primary AML in secondary
recipients including cells (for the Lym+kit+ and Gr1+kit+ compart-
ments) of a less differentiated immunophenotype (Linkit+) as
well as cells with a phenotype corresponding to mature cells of
the opposite lineage (i.e., Gr1+kit+ cells produced cells express-
ing lymphoid markers and vice versa; Figure 2A). To determine
whether this immunophenotypic recapitulation was clonal, single
Lym+kit+ and Gr1+kit+ cells were expanded into colonies that
were injected into secondary recipients (Figure 2Bi). Two of
twenty recipients, transplanted with colonies derived from single
Lym+kit+ and Gr1+kit+ cells, respectively, developed AML and.
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Multiple Tumor-Initiating Cells in H9M AMLthese leukemias again recapitulated the complete immunophe-
notypic spectrum (Figure 2Bii). Moreover, pre-leukemic H9M-
transduced progenitors expressing myeloid markers (CD11b+
Gr1+) gave rise to the immunophenotypic spectrum when trans-
planted to primary recipients (Figure S3), confirming that
enforced H9M expression permits cells with defined lineage
commitment to assume immunophenotypes of ‘‘earlier’’ or alter-
nate lineages, and that traditional phenotypes associated with
developmental stage specificity are separable from TIA.
Dynamic Hierarchy in Secondary AML
To determine whether secondary tumors had the same hierar-
chical tumorigenic capacity as the primary tumors, 100 Linkit+,
Lym+kit+, Gr1+kit+, or Gr1+kitlo cells from secondary AML were
transplanted into tertiary recipients. As in primary AML, all ani-
mals transplanted with 100 Linkit+ or Lym+kit+ cells from
secondary AML succumbed rapidly to disease (Figures 2C and
2D). Strikingly, although no animals transplanted with 100 Gr1+
kit+ cells from primary AML-developed leukemia, all animals
transplanted with 100 Gr1+kit+ cells from secondary AML devel-
oped fatal AML indistinguishable (except longer latency, 38 v.
23days,p=0.002, log-rank test) from tumorsarising fromLinkit+
or Lym+kit+ subsets (Figure 2E). As before, Gr1+kitlo cells failed
to reconstitute tumors (Figure 2F), demonstrating a continued
lack of TIA in this fraction. Thus, although TIA does not remain
fixed within immunophenotypic compartments as tumors prog-
ress, H9M AML remains hierarchically organized in secondary
disease as TICs give rise to terminal blasts without TIA.
To determine whether H9M AML, like normal hematopoiesis,
has a directional developmental progression, we transplanted
cohorts of mice with each primary TIC and sacrificed groups of
mice sequentially to assess the immunophenotypes of leukemic
progeny as well as capture individual variability of leukemic
expansion (Figure 3A). GFP+ cells were first detectable on
day 7 posttransplantation. SPADE analysis showed substantial
heterogeneity in immunophenotypic reconstitution prior to day
14, after which nearly all mice (11/12) consolidated to a uniform
immunophenotypic equilibrium that was nearly identical to
primary AML (Figures 3B–3Diii and Figure S4). Thus, although
each TIC ultimately recapitulated the immunophenotypic spec-
trum of primary AML, unlike in normal development, the in vivo
developmental program did not appear to follow a strict direc-
tional progression. Whether the regeneration occurs by a trans-
differentiation-like mechanism or dedifferentiation followed by
forward differentiation remains to be determined, given that it
is rapid and beyond the current level of resolution.
TICs Share Genetic, Signaling and Survival Pathways
We hypothesized these phenotypically distinct TICs, which
shared biological and developmental potential, would utilize
overlapping genetic, signaling, and survival pathways, and tar-
geting such shared pathways could affect TIC survival. Microar-
ray analysis and unsupervised hierarchal clustering were
performed on TICs from primary H9M AML, populations from
MLL-AF9 AML with high or low TIA (Mac1+kit+ or Mac1+kitlo,
respectively) (Somervaille andCleary, 2006), andanalogous pop-
ulations from WT-GFP marrow (Linkit+, Lym+, and Gr1+) (Fig-
ure 4A). This analysis showed H9M Linkit+ and Lym+kit+
compartments clustered with normal HSPCs (GFP:Linkit+),CeH9M Gr1+kit+ cells clustered with the Mac1+kit+ TIC from MLL-
AF9 AML, and terminal blasts clustered together (H9M:Gr1+kitlo
and MLL-AF9:Mac1+kitlo). This suggests that TICs in primary
H9M AML (Linkit+ and Lym+kit+) share a genetic signature
resembling normal HSPCs, as occurs in human AML (Eppert
et al., 2011), and is distinct from the program utilized in MLL-
AF9 TICs.
To determine whether primary H9M TICs shared enrichment
for leukemogenesis-associated genes, we assessed the top
2500 differentially expressed probes between Linkit+ and
Lym+kit+ cells relative to primary Gr1+kit+ cells (which lacked
TIA) and identified common genes (Table S1). GO-term enrich-
ment analysis of the resultant 151 genes (94 with annotations)
showed the major biological functions were cellular metabolism
(26%), signal transduction regulation (19%), and transcription/
chromatin organization (18%) (Figure 4B). Specifically, this list
included targets whose improper regulation has been previously
implicated in AML such as Satb1, Dnmt3a, and Msi2 (Kharas
et al., 2010; Ley et al., 2010; Steidl et al., 2007). Therefore,
primary H9M TICs shared expression of genes implicated in
leukemogenesis, suggesting a core cellular program can be
induced by H9M expression—although the roles of these genes
as drivers or passengers remains to be elucidated. Despite this
shared program, these populations are unique: 12 of the top
20 genes differentially expressed between them have roles in
B cell development, Lym+kit+ cells express B220, and Lym+kit+
cells have rearranged the D-J gene segments on the immuno-
globulin heavy chain locus (Figure S5). Therefore, the Lym+kit+
population represents a lymphoid-specified AML TIC, potentially
analogous to other lymphoid-primed AML TICs (Deshpande
et al., 2006; Goardon et al., 2011).
To determine whether TICs shared signaling networks,
we utilized mass cytometry (Bendall et al., 2011) to provide
a single-cell view of TIC signaling architecture. After measuring
potentiated phosphorylation of 14 intracellular nodes in each
TIC after cytokine stimulation, analysis of variance (ANOVA)
was utilized to test for statistically significant differences in the
fold-change values (FCV) between TICs for each stimulation-
phospho node pair (Figure 4B). This analysis showed no statisti-
cally significant differences in the FCV for 26 of 28 conditions
tested (Figure S6A), demonstrating these distinct TICs have
largely conserved signaling networks (unlike WT samples in
which FCV between compartments were significantly different
for three of five conditions [Figure S6B]).
To determine which nodes had conserved roles in TIC prolifer-
ation, we sorted each compartment into liquid media supple-
mented with S36GM—which selectively expands TICs but not
terminal blasts in vitro—and assessed proliferation after 7 days
in the presence of pharmacological inhibitors targeting a suite
of cellular pathways implicated in TIC maintenance (Figure 4D).
For inhibitors targeting the MAP kinase pathway (Mek inhibitor
PD-0325901), DNA methyltransferase (5-aza-20-deoxycytidine),
receptor tyrosine kinases (imatinib), and PI3K/Akt (GDC-0941),
termed class I inhibitors, the IC50 values for each TIC were over-
lapping or within 5-fold, suggesting these nodes play conserved
roles in TIC survival and proliferation. In contrast, inhibitors tar-
geting Src-family kinases (dasatinib) and mTOR (KU-0063794),
class II inhibitors, had IC50 values greater than 10-fold different
in the TICs, suggesting disparate requirements for thesell Stem Cell 10, 210–217, February 3, 2012 ª2012 Elsevier Inc. 213
Figure 3. In Vivo Tumorigenic Differentiation Does Not Proceed Along a Strictly Defined Pathway
(A) Experimental scheme. Defined numbers of each TIC in primary AML were transplanted into cohorts of secondary recipients. Animals were sacrificed every
3–4 days thereafter so that the frequency and immunophenotype of progeny could be assessed.
(B–D) SPADE analysis of bonemarrow of individual mice transplantedwith (B) 500 Linkit+ cells, (C) 500 Lym+kit+ cells, or (D) 2500Gr1+kit+ cells on (i and ii) day 11
post transplant or (iii) 19–21 days posttransplant. Shaded regions in (i) and (ii) are the compartment transplanted and in (iii) are compartments present in primary
leukemia. See also Figure S4.
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Multiple Tumor-Initiating Cells in H9M AMLpathways across TICs. Collectively, these proliferation and
signaling data show that overlapping survival and signaling no-
des govern phenotypically distinct TICs.
Targeting Conserved Nodes In Vivo Increases Survival
We hypothesized that pathways with conserved roles in TIC
survival could serve as effective therapeutic targets in vivo while
those with disparate roles would not. To determine if conserved
signaling pathways were essential for AML maintenance in vivo,
secondary recipients transplanted with total GFP+ H9M marrow
were treated with either class I (PD-0325901, 5-aza-20-deoxycy-
tidine) or class II (Dasatinib) inhibitors starting 2 weeks after
transplant to allow for immunophenotypic reconstitution. All214 Cell Stem Cell 10, 210–217, February 3, 2012 ª2012 Elsevier Incmice treated with vehicle or the class II inhibitor dasatinib (with
10-fold differential selectivity across the TICs) succumbed
rapidly to AML (median survival 25 days; Figure 4E). Strikingly,
mice treated with the class I inhibitors PD-0325901 and 5-aza-
20-deoxcytidine had statistically significant increases in overall
survival (median survival 37 days, p = 0.01 and 42 days, p <
0.001, respectively, log-rank test). These results show that in vivo
pharmacologic targeting of pathways with conserved roles in
TIC cell survival in vitro significantly increased survival, suggest-
ing that phenotypically distinct TICs rely on conserved survival
nodes in vivo and targeting nodes only important for certain
classes of TIC allows for other TICs to ‘‘escape’’ and for disease
to rapidly progress..
Figure 4. Phenotypically Distinct TICs Have Conserved Signaling and Survival Networks & Targeting Conserved Nodes in vivo Increases
Survival
(A) Hierarchical clustering of phenotypic compartments from primary H9M AML (H9M: Linkit+, Lym+kit+, Gr1+kit+, Gr1+kitlo), populations from MLL-AF9 AML
with high or low TIA (MLL: Mac1+kit+ or Mac1+kitlo, respectively), and analogous populations from GFP marrow (GFP: Linkit+, Lym+, and Gr1+). Each line
represents a unique biological replicate.
(B) GO analysis of genes upregulated in primary H9M TICs (Linkit+ and Lym+kit+) relative to the Gr1+kit+ compartment based on biological process annotations.
See also Figure S5 and Table S1.
(C) Heatmap of the phospho-response in TICs (colored bar indicates compartment) isolated from secondary AML, measured by mass cytometry. ANOVA was
used to test for statistically significant differences in fold-change values between TIC in all mice tested (n = 3). Asterisks indicate statistically significant differences
(p < 0.05). See also Figure S6.
(D) Defined numbers of cells from each TIC (Linkit+, blue; Lym+kit+, red; Gr1+kit+, green) were sorted into liquid medium with S36GM and concentrations of
inhibitors for the pathways indicated above the plots. Plots represent cell numbers after 7 days measured in quadruplicate ± SEM.
(E) Survival curves of secondary mice transplanted with 104 total GFP+ primary AML marrow cells treated with dasatinib, PD-0325901, and 5-aza-20-deoxy-
cytidine. Survival differences betweenmice treated with vehicle and PD-0325901 (p = 0.01, log-rank test) or 5-aza-20-deoxycytidine (p < 0.0001, log-rank test) are
statistically significant.
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Our data support the central tenet of the CSC model, i.e., hierar-
chical tumor organization. In H9M AML, self-renewing TICs with
multilineage potential gave rise to terminal blasts (Gr1+kitlo)
unable to regenerate the tumor. However, this hierarchy existedCeoutside the strict phenotypic and unidirectional developmental
bounds characterizing normal hematopoiesis and other
leukemic systems (Goardon et al., 2011; Sarry et al., 2011)
such that TIA was decoupled from stable immunophenotype or
stage specificity. Notably, TICs had overlapping enrichment of
leukemic- and HSPC-associated gene signatures, signalingll Stem Cell 10, 210–217, February 3, 2012 ª2012 Elsevier Inc. 215
Cell Stem Cell
Multiple Tumor-Initiating Cells in H9M AMLnetworks, and survival determinants, and pharmacological tar-
geting these shared pathways in vivo significantly improved
host survival. Therefore, the ability to initiate disease (or ‘‘cancer
stemness’’) can represent a coordinately regulated cellular state
as opposed to a defined cell phenotype.
This view provides context to the disparate results regarding
the nature of AML CSCs (Bonnet and Dick, 1997; Goardon
et al., 2011; Sarry et al., 2011; Somervaille and Cleary, 2006;
Taussig et al., 2010). Much of the controversy regarding CSCs
comes from the notion that the CSC model’s implications are
mutually exclusive from other views. That is, either cancer repre-
sents a caricatured developmental process with a strictly
defined CSC population or stochastic disequilibrium rules, with
every cell being an equally bad agent. In this retroviral, LTR-
driven model with a single oncogenic initiating event in a geneti-
cally homogenous background with syngeneic recipients, the
frequency and phenotype of cells with TIA in the resultant oligo-
clonal disease are dynamic. It is therefore not surprising that in
human AML, driven by numerous genetic lesions in genetically
diverse backgrounds, and where CSC activity is assayed across
a xeno-barrier, disparate interpretations could arise. Although it
remains to be seen whether phenotypic interconversion and
a tumor-initiating ‘‘stem cell state’’ that appears to transit
between different cellular phenotypes is a general CSC mecha-
nism or is confined to rare oncogene sets, these results add
a new layer of complexity to the heterogeneity underlying normal
and leukemic stem cell systems (Anderson et al., 2011; Gibbs
et al., 2011; Notta et al., 2011). Although stable hematopoietic
marker expression proved unreliable in isolating H9M TICs, we
believe identifying CSC surface markers does have important
mechanistic and therapeutic value (Jin et al., 2009; Majeti
et al., 2009). Future work must elucidate molecular modules
endowing TIA, identify consistent CSC markers or pathways,
and unravel targetable signaling events conserved in—but not
necessarily exclusive to—CSC survival.
EXPERIMENTAL PROCEDURES
Vectors, Generation of H9M AML, and Colony Formation Assay
H9M AML was generated and colony-forming assay was done as previously
described (Majeti et al., 2009; Somervaille and Cleary, 2006). Animal studies
were done in compliance with the Stanford Administrative Panel on Laboratory
Animal Care Protocol 15986.
Gene Expression Profiling
Total RNA from 5 3 103105 TICs was purified by RNAqueous kit (Ambion).
Microarray hybridization probes were synthesized from total RNA; RNA was
amplified with the Ovation Pico WTA kit and biotin labeled with the Encore
Biotin Module (NuGEN). Probes were hybridized to Affymetrix Mouse Genome
430 2.0 arrays. The primary data were quantile normalized and analyzed with
RMAexpress software. Unweighted hierarchal clustering was performed with
Spotfire.
Mass Cytometry and SPADE Analysis
Stimulation, antibody preparation cell staining, and data analysis were per-
formed on the basis of procedures previously described (Bendall et al.,
2011). In brief, H9M AML cells were rested in culture media for 90 min at
37C, stimulated with S36GM (100 ng/ml SCF and 20 ng/ml IL-3, IL-6, and
GM-CSF) for 15 min, fixed with 1.6% paraformaldehyde for 10 min at 25C,
stained with surface markers for 30 min at 25C, permeabilized with ice-
cold, 100% methanol at 80C overnight, and stained with intracellular anti-
bodies 30 min at 25C. Mass cytometry antibodies are described in Table S2.216 Cell Stem Cell 10, 210–217, February 3, 2012 ª2012 Elsevier IncIn Vitro Drug Screen
Culture medium (IMDM with 10% FCS + penicillin/streptomycin/gluatmine +
25 mM HEPES, and nonessential amino acids [GIBCO]) supplemented with
S36GM cocktail and inhibitor were added to 96-well plates. Defined cell
numbers were clone sorted into wells as 4-fold replicates and cultured for
7 days at 37C. Cell number was calculated by flow cytometry (BDTruCount
beads) and normalized to the highest individual replicate for a specific cell
population and inhibitor. Statistical analysis, least-squares regression, and
IC50 values were calculated with GraphPad Prism. PD-0325901, dasatinib,
imatinib, KU-0063794, and GDC-0941 purchased from Selleck Chemicals;
5-aza-20-deoxycytidine was purchased from Sigma-Aldrich.
In Vivo Pharmacological Inhibition
Ten-week-old, C57BL/6 mice were sublethally irradiated (4.8 Gy) and trans-
planted with 104 total GFP+ marrow cells from primary H9M mice and
5 3 104 helper marrow cells. Treatment began 13 days after transplantation.
Vehicle (0.5% HPMC/0.05% Tween-80 solution; daily) and Dasatinib
(10 mg/kg d13-23) were administered via oral gavage until mice were mori-
bund. PD-0325901 was administered via oral gavage (25 mg/kg on d13-
18 and 15 mg/kg on d23-26 posttransplantation). 5-Aza-20-deoxycytidine
(0.25 mg/kg in PBS) was administered three times per week (d14, 17, 20,
22, 24, 27) via intraperitoneal injection.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.stem.2012.01.004.
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